Close
  Indian J Med Microbiol
 

Figure 2: (a-d) Tumor showing immunopositivity for CD20, CD10, BCL-6, and MUM1 respectively, (e and f) Tumor showing immunonegativity for BLIMP1 and BCL-2, respectively, (g) MIB1 labeling index of 90%–95%, (h) fluorescent in situ hybridization for interferon regulatory factor 4 dual-color break-apart probe showing split red/green signals in 90%–95% of tumor nuclei

Figure 2: (a-d) Tumor showing immunopositivity for CD20, CD10, BCL-6, and MUM1 respectively, (e and f) Tumor showing immunonegativity for BLIMP1 and BCL-2, respectively, (g) MIB1 labeling index of 90%–95%, (h) fluorescent <i>in situ</i> hybridization for interferon regulatory factor 4 dual-color break-apart probe showing split red/green signals in 90%–95% of tumor nuclei